T3 Companies’s IGC Pharma IGC Stock Holding History

T3 Companies’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$5.26K	–	206
2026 Q1	$5.26K	Hold	20,000	–	–	0.01%	133
2025 Q4	$5.63K	Buy	+20,000	New	+$7.13K	0.01%	170

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

T3 Companies's IGC Position: Q2 2026 in Review

T3 Companies sold out of IGC Pharma (IGC) in Q2 2026, closing a stake of 20,000 shares — an estimated $5.26K sold.

T3 Companies first reported a position in IGC in Q4 2025 and held it in 2 quarters. The position peaked at $5.63K in Q4 2025. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

T3 Companies reported no remaining IGC Pharma position as of Q2 2026 after selling out during the quarter.
T3 Companies sold 20,000 IGC Pharma shares in Q2 2026, an estimated $5.26K.
T3 Companies first reported a position in IGC Pharma in Q4 2025 and held it in 2 quarters.
T3 Companies's IGC Pharma position peaked at $5.63K in Q4 2025.
36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.